• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

LCI Launches Screening Saves Program

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Odronextamab Elicits Responses in Some With Lymphoma Following CAR-T

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Air Matters: Radon and the Environment

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Overcoming Barriers to Emotional and Physical Support in Cancer Care

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles An expert sat down to discuss the emotional and physical barriers patients may face when seeking support for fear of cancer progression. Read More

Remission is Not a Cure for Follicular Lymphoma, or Any Cancer

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss. Read More

First Patient with CD5-Postivie T-Cell Lymphoma Dosed with MB-105

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105. Read More
« Older Entries
Next Entries »

Recent Content

  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
  • What Should Patients with Multiple Myeloma Know After ASCO 2025?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT